Catching cancer cells early, before they establish themselves elsewhere
For men facing prostate cancer surgery with the most aggressive tumors, medicine has long struggled to answer a quiet but urgent question: is removing the gland enough? A major phase 3 trial called PROTEUS now offers a compelling answer — that surrounding surgery with a dual hormone blockade using apalutamide and androgen deprivation therapy meaningfully reduces the risk of cancer spreading and of death, suggesting that high-risk disease demands a more ambitious response from the very beginning.
- High-risk prostate cancer patients face a sobering reality: even after surgery, aggressive tumors can escape and establish themselves elsewhere in the body.
- The PROTEUS trial revealed that adding apalutamide to standard hormone therapy before and after surgery produced substantial reductions in metastatic disease and death — results striking enough to prompt serious reconsideration of current protocols.
- The dual blockade strategy targets male hormones from two directions simultaneously, aiming to neutralize cancer cells during the perioperative window when they may be most likely to spread.
- Side effects including hot flashes, bone loss, and sexual dysfunction remain real costs, but for men with aggressive tumors, the survival benefit appears to outweigh the burden.
- Oncologists are now weighing whether this regimen should become the default standard of care, potentially reshaping treatment guidelines and clinical conversations for thousands of patients each year.
A phase 3 clinical trial has shown that men with high-risk prostate cancer who receive a combination of two hormone-based drugs surrounding their surgery fare significantly better than those who undergo the procedure alone. The PROTEUS trial, testing apalutamide — developed by Johnson & Johnson — paired with androgen deprivation therapy, demonstrated meaningful reductions in both metastatic disease and death among patients whose tumors carried markers of aggressive behavior.
Prostate cancer surgery is a cornerstone of treatment for localized disease, but outcomes diverge sharply based on how likely a tumor is to return. For men with high-risk features, oncologists have long sought systemic therapies that could improve survival beyond what surgery alone can achieve. The PROTEUS trial directly addressed this gap by enrolling high-risk patients and assigning one group to the combination hormone regimen while the other received standard surgical care.
The biology behind the approach is deliberate: apalutamide blocks androgen receptors on cancer cells, while androgen deprivation therapy suppresses hormone production at the source. Together, they create a dual blockade during the perioperative window — the period when micrometastatic cells may be most vulnerable to interception. Starting treatment before surgery, rather than waiting for recurrence, appears to catch the disease at a more controllable stage.
The clinical implications are significant. If adopted as standard of care, this regimen could benefit thousands of men annually. Hormone therapy does carry side effects — hot flashes, sexual dysfunction, bone loss — but for patients facing aggressive disease, the trade-off appears justified. The PROTEUS findings are expected to influence treatment guidelines and fundamentally shift how urologists and oncologists approach the months surrounding surgery for high-risk patients.
A phase 3 clinical trial has demonstrated that men with high-risk prostate cancer who receive a combination of two hormone-based drugs before surgery have significantly better outcomes than those undergoing the procedure alone. The PROTEUS trial tested apalutamide—a drug made by Johnson & Johnson—paired with standard androgen deprivation therapy, administered in the weeks and months surrounding the surgical date. The results, presented at a major oncology conference, showed that this perioperative approach reduced both the risk of cancer spreading to other parts of the body and the risk of death in patients whose tumors carried markers suggesting aggressive behavior.
Prostate cancer surgery remains a cornerstone of treatment for men whose disease appears confined to the gland, but outcomes vary dramatically depending on how likely the cancer is to return. Surgeons and oncologists have long sought ways to improve survival in the subset of patients whose tumors show high-risk features—characteristics that predict a greater chance of recurrence even after the prostate is removed. For these men, the question has been whether adding systemic therapy before or after surgery could tip the scales in their favor.
The PROTEUS trial enrolled men with localized prostate cancer deemed at high risk of progression. One group received apalutamide plus androgen deprivation therapy starting before surgery and continuing through the recovery period. The other group received standard surgical care without the additional hormone treatment. When researchers followed these patients over time, the combination therapy group showed meaningful reductions in the rates of metastatic disease and death. The magnitude of benefit was substantial enough that oncologists and surgeons are now considering whether this regimen should become the default approach for high-risk surgical candidates.
Apalutamide works by blocking androgen receptors, preventing cancer cells from receiving growth signals from male hormones. Androgen deprivation therapy suppresses the production of those hormones in the first place. Together, they create a dual blockade that appears particularly effective in the perioperative window—the vulnerable period when cancer cells may be most likely to escape the primary tumor and establish themselves elsewhere. By starting treatment before surgery rather than waiting until after, physicians may be catching and controlling micrometastatic disease at an earlier, more treatable stage.
The implications for clinical practice could be substantial. If this regimen becomes standard of care for high-risk localized prostate cancer, thousands of men annually might benefit from improved survival and reduced cancer progression. The trial results suggest that the combination is tolerable enough for perioperative use, though hormone therapy does carry side effects including hot flashes, sexual dysfunction, and bone loss that accumulate with duration of treatment. For men facing surgery with aggressive tumors, however, the trade-off appears worthwhile.
Oncologists have emphasized that this finding represents a shift in how they think about surgical prostate cancer. Rather than viewing surgery as the definitive treatment with hormone therapy reserved for cases where cancer recurs, the new evidence supports treating high-risk disease more aggressively from the outset. The PROTEUS data will likely influence treatment guidelines and reshape conversations between urologists and their patients about what happens in the months surrounding surgery. For men diagnosed with high-risk prostate cancer, this trial opens a pathway to potentially better long-term survival—a meaningful development in a disease where outcomes have historically been difficult to predict and control.
Citas Notables
This represents a practice-changing approach to high-risk localized prostate cancer, potentially becoming new standard of care— Trial results and oncology consensus
La Conversación del Hearth Otra perspectiva de la historia
Why does timing matter so much? Why not just give these drugs after surgery if the cancer comes back?
Because by then, cancer cells may have already spread beyond reach. The perioperative window—right around surgery—seems to be when micrometastases are most vulnerable. You're catching them early, before they establish themselves in bone or organs.
So this is about prevention rather than treatment?
Exactly. In high-risk patients, we know recurrence is likely. This isn't waiting to see if cancer returns; it's assuming it might and suppressing it before it has a chance to grow.
What's the actual survival difference we're talking about?
The trial showed meaningful reductions in metastatic disease and death rates, though the exact percentages matter less than the direction: fewer men died, fewer developed spread cancer. That's the signal oncologists were looking for.
Does every prostate cancer patient need this?
No. This is specifically for high-risk disease—tumors with aggressive features. Standard-risk patients undergoing surgery don't need it. The key is identifying who's actually at high risk before surgery.
What about side effects? Hormone therapy isn't gentle.
It's not. Hot flashes, erectile dysfunction, bone loss. But for a man facing a tumor likely to kill him, a few months of those side effects is a reasonable trade.
Will this change what surgeons actually do?
It should. Guidelines will likely shift, and urologists will start recommending this combination to high-risk patients. Whether it becomes truly standard depends on how quickly the medical community adopts it.